Boehringer launches 81% discounted biosimilar of AbbVie's Humira

Germany's Boehringer Ingelheim on Monday launched an unbranded version of its biosimilar of AbbVie's (ABBV.N) Humira with a list price 81% cheaper than the blockbuster rheumatoid arthritis drug.

The company in July launched a branded biosimilar, Cyltezo, priced at a 5% discount to Humira's current list price of $6,922 per month. Boehringer's close-copies of Humira are the only ones that can be substituted for the original without consulting the prescriber after being designated as interchangeable by the U.S. Food and Drug Administration.